COMPASS Pathways (NASDAQ:CMPS) Given Buy Rating at HC Wainwright

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $45.00 price target on the stock.

A number of other equities analysts also recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. Stifel Nicolaus initiated coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group decreased their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways presently has a consensus rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Stock Performance

Shares of CMPS stock traded up $0.06 during mid-day trading on Tuesday, hitting $3.73. The stock had a trading volume of 604,855 shares, compared to its average volume of 724,331. COMPASS Pathways has a fifty-two week low of $3.17 and a fifty-two week high of $12.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company’s 50-day simple moving average is $4.06 and its 200-day simple moving average is $5.21. The firm has a market cap of $255.21 million, a PE ratio of -1.70 and a beta of 2.28.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Sell-side analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. RTW Investments LP acquired a new position in COMPASS Pathways during the fourth quarter worth approximately $11,714,000. Altium Capital Management LLC purchased a new position in shares of COMPASS Pathways in the 4th quarter worth $5,384,000. Nantahala Capital Management LLC boosted its holdings in COMPASS Pathways by 400.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,780,000 after acquiring an additional 800,000 shares during the last quarter. Tang Capital Management LLC acquired a new stake in COMPASS Pathways during the fourth quarter worth about $3,780,000. Finally, Sio Capital Management LLC lifted its stake in shares of COMPASS Pathways by 211.7% during the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after purchasing an additional 621,222 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.